Business Wire

CA-MULTEFIRE-ALLIANCE

19.11.2020 15:02:06 CET | Business Wire | Press release

Share
MFA Launches MulteFire 1.0 Certification Program to Support Interoperable Device Ecosystem for Private Wireless Networks

The MulteFire Alliance (MFA) today announced the launch of its MulteFire 1.0 Certification Program. In addition, the first customer premise equipment (CPE) device has been certified compliant.

With MulteFire technology, organizations can now cost-effectively deploy their own private LTE network and realize the benefits of better capacity, coverage, mobility and built-in security needed for industry 4.0 use cases.

The MulteFire 1.0 specification defines LTE operation in unlicensed and shared spectrum bands, including the global 5 GHz band. The certification program tests eNodeBs together with UEs for conformance with the MulteFire 1.0 specification to ensure an interoperable, global device ecosystem for use in unlicensed or shared radio spectrum. By removing the need for licensed spectrum, MulteFire will help to lower entry cost and accelerate high-speed, secure private wireless networking deployment.

MulteFire technology opens up an entirely new range of private wireless use cases that add to existing deployment scenarios in asset-intensive industries. New opportunities include rapid deployment situations such as field hospitals and emergency response, as well as temporary systems for pop-up events, touring, cultural and sports programs. In addition, MulteFire can also be used to complement existing private wireless deployment in licensed spectrum, for example to add capacity by tapping into the large bandwidth available in the unlicensed 5 GHz spectrum band.

“The MulteFire 1.0 Certification Program is a significant milestone for the Alliance and represents the diligent efforts of our Certification Working Group to bring this program to the industry,” said Mazen Chmaytelli, president, MFA. “We are also excited to share that we have already certified the first MulteFire radio and device solutions from Nokia as compliant.”

“By enabling private wireless connectivity in unlicensed and shared spectrum, we enable even more enterprises to deploy their own private LTE and 5G networks,” said Stephan Litjens, General Manager, Nokia Digital Automation Cloud and MFA board chair. “As a founding member of MFA, we’re firmly at the forefront of this initiative – firstly with certification of our own MulteFire CPE offering – and also to accelerate a device ecosystem for the benefit of enterprise digital transformation.”

Through overlapping membership with 3GPP, the MFA is also supporting efforts for 5G NR standalone operation in unlicensed spectrum. A recent ABI Research white paper quantifies the total addressable market size for private network equipment (for industrial manufacturing, ports, logistics, mining, and energy) in LTE and 5G at $32.37B by 2030. ABI also states that by 2030 more than half of industry verticals’ private networks using LTE or 5G will be deployed in unlicensed, shared or dedicated licensed spectrum.

DEKRA Named Authorized Test Lab for MulteFire 1.0

DEKRA , an MFA member and leader in product certification, conducted the certification testing for MulteFire 1.0 and DEKRA Malaga has been named an Authorized Test Lab for the MulteFire 1.0 Certification Program. DEKRA was already named the first Authorized Test Lab for the MulteFire 1.9 GHz sXGP Certification Program launched in Japan at the end of 2019.

“DEKRA is very pleased to continue its partnership with the MFA with the addition of MulteFire 1.0 testing to our services offering, and we are happy to contribute to the success of the MulteFire ecosystem,” said Andrés Moreno, Managing Director, DEKRA Testing and Certification Spain.

The MFA Certification Program is available to all MFA members. Upon device certification, companies will receive the ‘MulteFire Certified’ logo and certification mark for product promotion and marketing purposes. The MFA welcomes membership from all companies that have an interest in private wireless networks. To join the MFA and for more details on membership levels, visit www.multefire.org/join .

For more information on the MFA Certification Program, visit www.multefire.org/certification-program/ .

Resources:

About the MFA

The MFA is an international association dedicated to building a global ecosystem in support of the common interests of members, developers and users in the application of Long Term Evolution (LTE) and next-generation mobile cellular technology, such as 5G New Radio, in configurations that use unlicensed or shared radio spectrum. For more information about MulteFire technology, its benefits, or how to become a member of the MFA, visit www.MulteFire.org .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye